Radiation therapy for bone metastases using fewer treatment sessions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of multi-fraction stereotactic body radiation therapy (SBRT) delivered in three treatment sessions compared to the standard five-session approach for patients with bone metastases. The primary focus is on assessing pain response three months after treatment. Participants will receive SBRT, and their pain levels will be monitored to determine if the shorter treatment regimen is equally effective. The study aims to provide a more efficient treatment option for patients suffering from pain due to bone metastases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Personally signed and dated written informed consent,
* Histological diagnosis of malignancy,
* Histologically or radiologically diagnosed bone metastasis,
* Age ≥ 18 years
* Pain or under pain control medication

Exclusion Criteria:

* Pregnant or lactating women,
* Women of childbearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment,
* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.,
* Prior radiotherapy to the intended treatment site,
* Lesions \> 5cm in maximum diameter,
* Prior treatment with radioactive isotopes within 30 days of randomisation,
* Spinal column, hands, feet, or head as intended treatment site,- Fracture at the intended treatment site,
* Surgery required or previous surgery at the intended treatment site
* Instability of the intended treatment site.

Where it's running

• Kantonsspital Winterthur
  Winterthur, Canton of Zurich, Switzerland Recruiting
• University Hospital Bern
  Bern, Switzerland Recruiting

Study contacts

• Principal investigator: Robert Foerster, MD — Kantonsspital Winterthur KSW
• Study coordinator: Robert Foerster, MD
• Email: robert.foerster@ksw.ch
• Phone: +4152 266 21 21

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Pelvic ultra-hypofractionated radiotherapy after surgery for high-risk endometrial cancer

  This trial tests whether giving 27.5 Gy in five sessions of pelvic radiotherapy after surgery is safe and feasible for high-risk endometrial cancer patients.

  Recruiting Instituto de Investigación Sanitaria Aragón · Zaragoza, Zaragoza · NCT07779109

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• Seeing what cancer patients eat during radiation treatment using a mobile food diary

  This study tests whether patients undergoing radiation therapy can consistently use a mobile food diary app to log their daily meals.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07682714

• Prophylactic Radiotherapy to Prevent Bone Complications in Metastatic Cancers

  This study tests whether giving early radiotherapy to high-risk bone metastases, in addition to standard care, can reduce bone-related problems in adults with metastatic solid cancers.

  Recruiting Phase 2 Institute of Oncology Ljubljana · Ljubljana · NCT07540650

• CAIX PET/CT–guided radiation for clear cell kidney cancer

  This trial will try using CAIX-targeted PET/CT scans plus FDG PET/CT to guide focused stereotactic radiation alongside standard targeted therapy and anti‑PD‑1 immunotherapy for adults with recurrent or metastatic clear cell kidney cancer.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07540260

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.